David Charles Rees

This inventor holds 26 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Cancer Therapeutics. Top assignees: Astex Therapeutics Limited, Warner-Lambert Company, Cancer Research Technology Limited. Active years: 1990-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Charles Rees. Retrieved from https://idiyas.com/inventor/david-charles-rees

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 5)

% Patents Active = 80.8

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 4.6

ph-index = 10

Forward Citations = 295(Granted Patents)

Location History:

Glasgow, GB (1997 - 1999)
Cambridge, GB (1990 - 2024)

Company Filing History:

15 out of 126

Astex Therapeutics Limited

patents

11 out of 2,538

Warner-Lambert Company

patents

5 out of 268

Cancer Research Technology Limited

patents

4. 1 out of 1

Cancer Research Technology Limtied

patent

5. 1 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

patents

where one patent can have more than one assignee

Years Active: 1990-2024

Loading Chart...

Areas of Expertise:

Isoindolinone Inhibitors

MDM2-P53 Interaction

Pyrazolyl Quinoxaline

Bicyclic Heterocycles

CDK Modulators

GSK Inhibitors

Aurora Kinases

Tachykinin Antagonists

Endothelin Antagonists

Analgesic Agents

Cholecystokinin Antagonists

Therapeutic Uses

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),

2. 11261171 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2022-03-01),

3. 10981898 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2021-04-20),

4. 10544132 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2020-01-28),

5. 10526311 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2020-01-07),

6. 9850228 - Pyrazolyl quinoxaline kinase inhibitors (2017-12-26),

7. 9464071 - Pyrazolyl quinoxaline kinase inhibitors (2016-10-11),

8. 9458158 - Bicyclic heterocycle compounds and their uses in therapy (2016-10-04),

9. 9155743 - Bicyclic heterocycle compounds and their uses in therapy (2015-10-13),

10. 8895601 - Pyrazolyl quinoxaline kinase inhibitors (2014-11-25),

11. 8778936 - Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases (2014-07-15),

12. 8497294 - Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases (2013-07-30),

13. 8293767 - 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors (2012-10-23),

14. 8110573 - Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases (2012-02-07),

15. 8013163 - 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors (2011-09-06),

Title: David Charles Rees: Innovator in Anticancer Research

Introduction: David Charles Rees is a prominent inventor based in Cambridge, GB, known for his significant contributions to the field of medicinal chemistry. With an impressive tally of 26 patents, Rees is recognized for developing innovative compounds aimed at combating cancer through novel therapeutic mechanisms.

Latest Patents: Among his recent inventions, Rees has focused on isoindolinone inhibitors of the MDM2-P53 interaction, which hold promise for anticancer activity. His invention encompasses compounds represented by a specific formula, as well as their tautomers, solvates, or pharmaceutically acceptable salts. These patents not only describe the compounds themselves but also outline pharmaceutical compositions containing these compounds, the methods for their synthesis, and their medical applications.

Career Highlights: Rees has made significant strides in his career by working with notable companies in the pharmaceutical industry. Some of the organizations he has been affiliated with include Astex Therapeutics Limited and Warner-Lambert Company. His expertise and innovative spirit have enabled him to develop impactful solutions in the realm of cancer treatment.

Collaborations: Throughout his career, Rees has collaborated with distinguished professionals in the field. Noteworthy coworkers include David Christopher Horwell and Steven Howard, both of whom have contributed to enhancing the research and development processes within their projects.

Conclusion: David Charles Rees embodies the spirit of innovation in pharmaceutical research and development. His extensive patent portfolio reflects his commitment to advancing medical science, particularly in the fight against cancer. As he continues to explore new frontiers in medicinal chemistry, Rees remains a valuable asset to the scientific community and a beacon of hope for those affected by cancer.

Profile summary based on public USPTO records.